Could AbbVie be a steal for investors as new meds take off? by Kyle Blankenship Friday, November 22, 2019 With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.
Merz splits into 3 businesses for better customer focus by Beth Snyder Bulik Thursday, November 21, 2019 Merz, going for a strong customer focus, recently did something many of its pharma peers have done: split into distinct operating businesses.
AbbVie plans $28B bond offering: Bloomberg by Eric Sagonowsky Monday, November 11, 2019 AbbVie is plotting a $28 billion bond sale to help fund its massive Allergan buyout, Bloomberg reports, the fourth largest in history.
New migraine hopefuls don't improve much on older meds: ICER by Eric Sagonowsky Thursday, November 7, 2019 While forthcoming migraine meds from Eli Lilly, Allergan and Biohaven do beat placebo, they're not much better than existing triptan drugs, ICER says.
Botox aside, what can AbbVie expect from Allergan post-merger? by Kyle Blankenship Tuesday, November 5, 2019 Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly.
Allergan pays $750M to settle Namenda 'hard switch' suit by Angus Liu Monday, October 28, 2019 The suit alleged Allergan tried to pull Namenda off the market right before patent expiration to force patients onto its long-acting version.
Allergan drives home the seriousness of glaucoma with new push by Beth Snyder Bulik Wednesday, October 30, 2019 Allergan’s new campaign “My Glaucoma” looks to raise awareness of the seriousness of the disease and uses real patients and caregivers.
Allergan backs mobile app for breast implant info exchange by Beth Snyder Bulik Friday, October 25, 2019 Allergan is backing the Aesthetic Society's development of an app for breast implant patients to store records and track safety.
